| dc.contributor.author | Farrell, R | en_US |
| dc.contributor.author | Baker, D | en_US |
| dc.date.accessioned | 2020-01-31T15:21:20Z | |
| dc.date.available | 2019-09-21 | en_US |
| dc.identifier.issn | 1473-9348 | en_US |
| dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/62582 | |
| dc.description.abstract | Spasticity is a frequent symptom in people with Multiple Sclerosis. Whilst many respond to first line therapies it is estimated that 30-40% will have suboptimal treatment response requiring more specialised management. Such strategies include combination of oral medications, botulinum toxin, nabiximols and consideration of intrathecal therapies; baclofen or phenol. Early expert intervention as outlined in this review can have a positive impact on functional ability and quality of life for people with MS. | en_US |
| dc.format.extent | 17 - 19 | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Advances in Clinical Neuroscience and Rehabilitation | en_US |
| dc.title | An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity | en_US |
| dc.type | Article | |
| pubs.issue | 5 | en_US |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Accepted | en_US |
| pubs.volume | 18 | en_US |
| dcterms.dateAccepted | 2019-09-21 | en_US |
| rioxxterms.funder | Default funder | en_US |
| rioxxterms.identifier.project | Default project | en_US |
